Ask AI
MASH Matters GI and Hepatology Practice

CE / CME

MASH Matters: New Evidence and Its Application to Gastroenterology and Hepatology Practice

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: June 23, 2025

Expiration: June 22, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Mazen Noureddin, MD, MHSc, discusses the pathophysiology of MASLD and MASH and the latest evidence on new and emerging MASH therapies.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded here or by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning and once at the end of the activity. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How often do you prescribe GLP-1 receptor agonists (RAs) to individuals with metabolic dysfunction–associated steatohepatitis (MASH) and obesity?

A 58-year-old person with obesity (BMI 34 kg/m2) on a GLP-1 RA for 2 years and dyslipidemia presents with fatigue and elevated liver function tests. A recent liver biopsy confirms steatohepatitis (MASH) with active disease (nonalcoholic fatty liver disease activity score = 6) and F3 fibrosis. The patient is concerned about the biopsy results and is eager to start treatment. Which of the following medications would be the most appropriate option for this person?

Which statement best characterizes semaglutide therapeutic potential in the management of MASH in patients with cardiometabolic risk factors according to the results of the phase III ESSENCE trial?

How often do you currently work with a multidisciplinary team to improve the care of patients with metabolic dysfunction–associated steatotic liver disease (MASLD)/MASH?

How many people with MASH do you provide care for in a typical week?

For those who practice in academic or community settings, please indicate your practice setting: